Sorin’s Phospholipid-Reducing Crown Valve Gains CE Mark

Cardiovascular device specialist Sorin Group, has gained CE mark certification for its innovative CROWN PRT™ stented aortic bioprosthesis.


In the treatment of aortic valve disease, the replacement of the native aortic valve with a stented bioprosthesis represents a standard technique to provide older patients with a performing and durable solution, while relieving them from the discomfort of lifelong oral anticoagulation therapy.

Built upon Sorin’s 45 years of experience in heart valve design and commitment to continuous innovation, CROWN PRT claims to be the latest advancement in stented aortic bioprosthesis technology, featuring surgeon-friendly design, PRT technology, state-of-the-art hemodynamic and durability performance.

CROWN PRT enables intuitive intraoperative handling through short rinse time, enhanced ease of implant through visible markers, as well as claimed improved radiographic visualization through dedicated X-ray markers.

The PRT suffix comes from the incorporation of Sorin’s  patented Phospholipid Reduction Treatment. The company says research which has demonstrated that phospholipids play a key role in the calcification process of bioprotheses and points out that its PRT has been shown to decrease phospholipid content in pericardial tissue thus leading to a remarkable reduction of calcium uptake compared to control.

Physician comments

“We are eagerly looking forward to implanting CROWN PRT, as this valve incorporates all the latest technological advancements in a modern bioprosthesis, enabling cardiac surgery procedures that are simple, reliable and reproducible,” said Professor Alain Leguerrier, Chief of the Cardio Thoracic and Vascular Surgery Department, Centre Hospitalier Universitaire de Rennes, France. “CROWN PRT meets all the conditions for a remarkable hemodynamic performance and an optimized durability.”

Company comments

“CROWN PRT promises to further advance our presence in tissue valve segments in Europe and globally. This new innovation for heart valve replacement is strategically designed to provide physicians with greater surgical versatility as well as outstanding durability, reinforcing Sorin’s brand promise to deliver industry-leading technologies in cardiac surgery,” said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group.

Source: Sorin Group

Share your thoughts

Your email address will not be published. Required fields are marked *